Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel

JAMA. 2024 Mar 26;331(12):1060-1061. doi: 10.1001/jama.2024.2985.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Anti-Retroviral Agents / therapeutic use
  • Diketopiperazines / therapeutic use
  • HIV Infections* / drug therapy
  • HIV Integrase Inhibitors / therapeutic use
  • Humans
  • Practice Guidelines as Topic
  • Pyridones / therapeutic use
  • Rilpivirine / therapeutic use
  • United States

Substances

  • Anti-HIV Agents
  • Anti-Retroviral Agents
  • cabotegravir
  • Diketopiperazines
  • Pyridones
  • Rilpivirine
  • HIV Integrase Inhibitors